dossier that passes in Europe may face rejection in India if Zone IVb data is missing. This makes zone mapping and compliance strategy essential for all companies with global market ambitions.

The Four ICH Climatic Zones Explained

The ICH model divides the world into four primary zones, with storage conditions tailored to temperature and humidity challenges:

• Zone I (Temperate): Includes Northern Europe, Canada, and parts of the U.S. Long-term testing is typically performed at 21–25°C and 45–60% RH.
• Zone II (Subtropical/Mediterranean): Southern Europe, Japan, parts of China. Long-term testing is conducted at 25°C/60% RH, with accelerated studies at 40°C/75% RH.
• Zone III (Hot/Dry): Middle Eastern countries and some African regions. Requires long-term studies at 30°C/35% RH.
• Zone IV (Hot/Humid): Further subdivided into:
  • Zone IVa: 30°C/65% RH (humid countries like Thailand, Philippines).
  • Zone IVb: 30°C/75% RH (very humid regions such as India, Brazil, and coastal Africa).

Zones IVa and IVb are particularly critical, as high humidity accelerates degradation, especially for hygroscopic drug products and biologics. Regulators in tropical regions will reject submissions that rely solely on Zone II or III data.

ICH Q1A(R2) and WHO TRS 953 Guidance

The cornerstone of global stability testing is ICH Q1A(R2), which harmonizes requirements for stability testing of new drug substances and products. It sets expectations for:

• Long-term, intermediate, and accelerated storage conditions.
• Minimum data requirements for submission (usually 12 months long-term, 6 months accelerated).
• Statistical analysis of stability trends per ICH Q1E.
• Extrapolation rules for shelf life beyond tested durations.

The WHO’s TRS 953 Annex 2 complements ICH by providing zone mapping for non-ICH member states. It ensures that countries in Latin America, Africa, and Asia — many falling under Zone IVb — have scientifically sound requirements aligned with ICH principles but adapted to their climates.

Regional Implementation of Climatic Zones

Although ICH provides the global framework, implementation differs across regulators:

• FDA (U.S.): Generally follows ICH Q1A(R2). Since the U.S. is mostly Zone II, FDA does not mandate Zone IV testing unless the sponsor seeks approval in tropical markets.
• EMA (Europe): Implements Zones I and II primarily, but European manufacturers exporting to Zone IV countries must demonstrate compliance for those conditions.
• CDSCO (India): Enforces Zone IVb conditions strictly. NDAs and ANDAs filed in India must include 30°C/75% RH stability data, even if global submissions do not.
• ANVISA (Brazil): Aligns with WHO TRS 953 and requires Zone IVb data for local registrations. Sponsors often need to generate additional data beyond ICH minimums.
• Other regulators (TGA Australia, Health Canada, Gulf regulators): Adapt ICH baselines but may request zone-specific justification during dossier review.

Case Examples: Climatic Zone Challenges

Case 1: OSD tablets in India. A European company filed an ANDA in India with only Zone II data. CDSCO rejected the application, citing lack of Zone IVb evidence. The sponsor lost 18 months while conducting new stability studies.

Case 2: Biologics in Brazil. A monoclonal antibody showed aggregation under Zone IVb conditions after 12 months. ANVISA restricted shelf life to 9 months, despite EMA approval for 24 months.

Case 3: WHO prequalification. A generic vaccine manufacturer failed WHO PQ due to missing Zone IV data. Without PQ status, the vaccine could not be procured by UN agencies, limiting market access.

Step-by-Step Global Compliance Checklist

1. Identify target markets early in development to determine which climatic zones must be covered.
2. Design stability protocols that include Zone IVb if submissions will be made in India, Brazil, or WHO-prequalified countries.
3. Select representative batches (three commercial-scale lots) for both API and drug product.
4. Use appropriate packaging designed to withstand humidity and temperature stress in Zone IV regions.
5. Conduct photostability studies to cover risks of light-sensitive products in tropical countries.
6. Apply bracketing and matrixing only with strong scientific justification — regulators are strict in Zone IVb.
7. Analyze data statistically (ICH Q1E) and avoid shelf life extrapolation unless fully justified.
8. Include zone-specific data in CTD Module 3 and summarize strategy in Module 2.3.
9. Prepare risk assessments for markets not directly tested, explaining bridging strategies.
10. Maintain ongoing stability commitments and report annual data to all relevant regulators.

Key Insights for Global Sponsors

Mapping stability requirements across climatic zones is not optional — it is a fundamental expectation for global pharmaceutical approvals. The FDA and EMA may not require Zone IV data, but regulators like CDSCO and ANVISA will. WHO prequalification further raises the stakes, as missing Zone IVb data can block entry into public health markets. The key to success lies in early planning: design global stability programs that integrate ICH Q1A(R2), WHO TRS 953, and regional adaptations. This proactive approach not only avoids regulatory delays but also accelerates time-to-market across diverse geographies.

Further Reading on Pharmaceutical Stability Studies

• FDA Stability Requirements
• Retest vs Expiry Dates
• ICH Q1B Photostability Testing
• Stability SOP: Building Compliance-Ready Procedures